Λεπτομέρειες βιβλιογραφικής εγγραφής
| Τίτλος: |
Merck KGaA Secures $11.3 Billion Purchase of Bio-Techne. |
| Συγγραφείς: |
Wind, Sonja (AUTHOR) |
| Πηγή: |
Bloomberg.com. 6/25/2026, pN.PAG-N.PAG. 1p. |
| Θεματικοί όροι: |
*Mergers & acquisitions, *Sales statistics, *Diagnostic services, *Economic efficiency, *Pharmaceutical industry, Life sciences, Scientific apparatus & instruments |
| Εταιρία/Οντότητα: |
Merck KGaA |
| Περίληψη: |
The article focuses on Merck KGaA's agreement to acquire Bio-Techne Corporation for approximately $11.3 billion to strengthen its life-science division. Merck, a German pharmaceutical and technology company, will pay $73 per share in cash, representing a 24% premium on Bio-Techne's recent closing price. Bio-Techne, a US-based diagnostics firm, provides research tools including lab-made proteins and antibodies, which Merck aims to integrate with its own products to offer a broader range of life-science solutions. The acquisition, Merck's largest since 2014, is expected to enhance sales growth, earnings margins, and generate significant cost synergies within three years. [Extracted from the article] |
|
Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Βάση Δεδομένων: |
Business Source Index |